Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 3 3
ROE
(2.69%) (5.21%) (2.85%) (4.20%)
ROA
(2.27%) (4.35%) (2.45%) (3.51%)
ROIC
(11.50%) (14.72%) (9.90%) (9.40%)
Return on Tangible Assets
(3.16%) (6.20%) (3.37%) (4.99%)
Average Days of Receivables
52.57 46.00 45.38 49.39
Free Cash Flow per Share
0.87 0.98 0.15 (0.01)
Free Cash Flow
25.42 28.37 4.56 (0.45)
Capital Expenditures
(36.36) (35.98) (43.69) (43.09)
Other line items
Cash ROIC
3.32% 3.63% 0.62% (0.06%)
Accounts Receivable Turnover
6.89 7.28 6.89 7.10
Accounts Payable Turnover
7.24 5.55 6.39 7.11
Inventory Turnover
9.05 7.73 8.69 8.58
Average Days of Payables
64.69 96.15 73.01 43.43
Days of Inventory on Hand
45.83 52.69 50.79 47.53
Tax Rate
(0.35) (0.18) (0.27) 0.01
Research and Development Expense of Revenue
14.59% 15.06% 15.79% 15.52%
Selling, General and Administrative Expense of Revenue
64.79% 66.62% 69.31% 68.20%
Share Based Compensation of Revenue
13.37% 13.33% 13.09% 12.56%
Interest Coverage
(226.84) (497.79) (163.99) (85.62)
Operating CF/Net income
(5.05) (2.66) (3.76) (2.20)
Depreciation/Fixed assets
0.44 0.38 0.12 0.13
Capex/Depreciation
(0.97) (0.98) (3.74) (3.28)
Revenue per Share
11.82 11.88 11.37 11.75
Operating CF per Share
2.13 2.22 1.61 1.40
Capex per Share
(1.25) (1.24) (1.46) (1.42)
Capex to Sales
0.11 0.10 0.13 0.12

Fold the line items

Columns are period end dates